Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
have some form of obstructive sleep apnea (OSA) Sleep apnea and obesity can create a vicious cycle, with each condition contributing to the other Both OSA and obesity can increase risk for type 2 diabetes, hypertension, cardiovascular conditions, and osteoarthritis Patient preferences often favor medication over CPAP, while providers tend to prefer CPAP therapy Tirzepatide (Zepbound ) received FDA approval for treating sleep apnea in patients with obesity in December 2024 Clinical trials show tirzepatide can reduce sleep apnea severity by approximately 50% Medicare Part D plans are beginning to cover tirzepatide specifically for sleep apnea treatment If you or someone you love struggles with obstructive sleep apnea (OSA), you know how challenging this condition can be
Improvements in these domains mean that GLP-1s may provide holistic mental support that enables patients to enter a positive spiral of life changes and reduce factors that can trigger relapse
The FDA label for Zepbound (tirzepatide for obesity) recommends reassessment of therapy at 16 weeks if less than 5% weight reduction has occurred [1]
People with higher starting BMIs often lose more weight in absolute terms
This is important because it gives your liver more time to produce the bile
